July 25, 2007-Siemens has agreed to acquire all outstanding shares of Dade Behring by submitting a cash offer to the Dade Behring shareholders of US $77 per common share. The planned acquisition has a total transaction volume of approximately US$7 billion. Closing is expected in the second quarter of fiscal year 2008, with completion of the merger subject to receipt of regulatory approvals and other customary closing conditions.
Headquartered in Deerfield, IL Dade Behring has operations in 35 countries and serves more than 25,000 customers around the world. The company provides clinical laboratory equipment and integrated solutions for routine chemistry testing, immunodiagnostics (including infectious disease testing), hemostasis testing and microbiology. In fiscal year 2006, Dade Behring realized sales of approximately US $1.7 billion.
"Demographic changes and increasing demand for higher quality healthcare systems represent a constant driver for growth in this sector," stated Peter Loscher, Chief Executive Officer of Siemens AG. “The impact of the Dade Behring acquisition on Siemens EPS (Earnings Per Share) is expected to be accretive from fiscal year 2010."
Erich R. Reinhardt, member of the Managing Board of Siemens AG and president of Siemens Medical Solutions added: "The acquisition of Dade Behring will create significant value for our shareholders. It will strengthen Siemens' position in the highly profitable and high-growth healthcare sector."
For more information: www.siemens.com
June 07, 2022 
